U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549


                                                February 5, 2025        

Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act



Dear Sirs,

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novo Nordisk A/S has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission on February 5, 2025.



Sincerely,


/s/ Lars Fruergaard Jørgensen/s/ Karsten Munk Knudsen

Lars Fruergaard Jørgensen
President and chief executive officer

Karsten Munk Knudsen
Executive vice president and
chief financial officer



Novo Nordisk (PK) (USOTC:NONOF)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025 Plus de graphiques de la Bourse Novo Nordisk (PK)
Novo Nordisk (PK) (USOTC:NONOF)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025 Plus de graphiques de la Bourse Novo Nordisk (PK)